TRVI Stock Analysis: Trevi Therapeutics | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 2.124m USD | 12M Return: 17.1% | US89532M1018 | Charts, Fundamentals & Technical Analysis

Haduvio, Nalbuphine, Chronic Cough, Pulmonary Fibrosis
Total Rating 26
Safety 49
Buy Signal -0.77
Pharmaceuticals
Sub-Industry Rotation: +10.2
Market Cap: 2.12B
Avg Turnover: 21.0M
Risk 3d forecast
Volatility66.2%
VaR 5th Pctl10.5%
VaR vs Median-3.68%
Reward TTM
Sharpe Ratio0.49
Rel. Str. IBD35.1
Rel. Str. Peer Group33.1 pctl
Character TTM
Beta-0.127
Beta Downside-2.274
Hurst Exponent0.558
Choppyness56.1%
Drawdowns 3y
Max DD39.08%
CAGR/Max DD3.04
CAGR/Mean DD9.05
EPS (Earnings per Share) EPS (Earnings per Share) of TRVI over the last years for every Quarter: "2021-09": -0.34, "2021-12": -0.28, "2022-03": -0.24, "2022-06": -0.14, "2022-09": -0.12, "2022-12": -0.06, "2023-03": -0.06, "2023-06": -0.07, "2023-09": -0.08, "2023-12": -0.08, "2024-03": -0.11, "2024-06": -0.12, "2024-09": -0.13, "2024-12": -0.11, "2025-03": -0.09, "2025-06": -0.09, "2025-09": -0.08, "2025-12": -0.06, "2026-03": -0.09, "2026-06": -0.11, "2026-09": -0.13,
Last SUE: 0.00
Qual. Beats: 0
Revenue Revenue of TRVI over the last years for every Quarter: 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.176, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0.146, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0, 2026-03: 0, 2026-06: 0, 2026-09: 0,
Last SUE: 0.00
Qual. Beats: 0

Warnings

Strong Share Dilution
High Debt While Negative Cash Flow
Below Avwap Earnings
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 7.5 years of data, until 10/2026

Jan +3.6% 0
Feb +5.8% 60
Mar +6.6% 0
Apr -2.1% 0
May -12.2% 0
Jun +12.0% 18
Jul +0.1% 0
Aug -6.8% 38
Sep +0.8% 0
Oct -10.1% 18
Nov -1.6% 0
Dec -0.6% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: TRVI Trevi Therapeutics

Trevi Therapeutics, Inc. (NASDAQ: TRVI) is a U.S.-based, clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut, focused on developing therapies for chronic cough associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. Its lead investigational product, Haduvio, is an oral extended-release formulation of nalbuphine, currently in a Phase 2b trial for chronic cough in IPF patients and a Phase 2a trial for refractory chronic cough. The company also holds a license agreement with Keenova Therapeutics plc covering nalbuphine hydrochloride formulations, and was incorporated in 2011 with its IPO completed in May 2019.

As a clinical-stage biopharmaceutical firm operating in the Pharmaceuticals sub-industry, Trevi Therapeutics has not yet commercialized a product and relies on R&D progress, licensing arrangements, and capital markets to fund its pipeline. The companys focus on repurposing an established opioid analgesic (nalbuphine) for chronic cough targets indications with limited existing treatment options.

Headlines to Watch Out For
  • Haduvio phase 2b IPF chronic cough data readout approaches
  • Refractory chronic cough phase 2a Haduvio trial results expected
  • Lillys gefapixant approval threatens Haduvio competitive positioning
  • Cash runway supports Haduvio development through key clinical catalysts
Piotroski VR-10 (Strict) 0.5
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.20 > 0.02 and ΔFCF/TA 2.24 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.20 > 3% & CFO -61.4m > Net Income -60.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 38.86 > 1.5 & < 3
Outstanding Shares: last quarter (142.5m) vs 12m ago -1.78% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.07%; Δ -0.07% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM)
Altman Z'' 10.00
A: 0.96 (Total Current Assets 305.8m - Total Current Liabilities 7.87m) / Total Assets 310.8m
B: -1.23 (Retained Earnings -382.2m / Total Assets 310.8m)
C: -0.25 (EBIT TTM -63.8m / Avg Total Assets 255.1m)
D: 37.58 (Book Value of Equity 302.8m / Total Liabilities 8.06m)
Altman-Z'' = 40.06 = AAA
What is the price of TRVI shares?

As of November 17, 2026, the stock is trading at USD 13.29 with a total of 1,635,715 shares traded. Over the past week, the price has changed by -13.19%, over one month by +11.87%, over three months by -28.08% and over the past year by +17.09%.

Current recommended Stop Loss: 12.10 (which is 9% or 1.3 ATR below the current price).

Is TRVI a buy, sell or hold?

Trevi Therapeutics has received a consensus analysts rating of 4.82. Therefore, it is recommended to buy TRVI.

  • StrongBuy: 9
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the TRVI price?
Analysts Target Price 28.2 112%
Trevi Therapeutics (TRVI) - Fundamental Data Overview as of 12 November 2026
Market Cap USD = 2.12b (2.12b USD * 1.0 USD.USD)
P/B = 6.7846
Revenue TTM = 0.0 USD
EBIT TTM = -63.8m USD
EBITDA TTM = -63.7m USD
Long Term Debt = 187k USD (estimated: total debt 527k - short term 340k)
Short Term Debt = 340k USD (from shortTermDebt, last quarter)
Debt = 527k USD (from shortLongTermDebtTotal, last quarter) (leases 527k already included)
Net Debt = -298.9m USD (calculated: Debt 527k - CCE 299.4m)
Enterprise Value = 1.83b USD (2.12b + Debt 527k - CCE 299.4m)
 Interest Coverage Ratio = unknown (Ebit TTM -63.8m / Interest Expense TTM 0.0)
 EV/FCF = -29.59x (Enterprise Value 1.83b / FCF TTM -61.7m)
FCF Yield = -3.38% (FCF TTM -61.7m / Enterprise Value 1.83b)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 132k) / Revenue TTM)
 Tobins Q-Ratio = 5.87 (Enterprise Value 1.83b / Total Assets 310.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 527k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -50.4m (EBIT -63.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 38.86 (Total Current Assets 305.8m / Total Current Liabilities 7.87m)
Debt / Equity = 0.00 (Debt 527k / totalStockholderEquity, last quarter 302.8m)
 Debt / EBITDA = 4.69 (negative EBITDA) (Net Debt -298.9m / EBITDA -63.7m)
 Debt / FCF = 4.85 (negative FCF - burning cash) (Net Debt -298.9m / FCF TTM -61.7m)
 Total Stockholder Equity = 244.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.82% (Net Income -60.8m / Total Assets 310.8m)
RoE = -24.81% (Net Income TTM -60.8m / Total Stockholder Equity 244.9m)
RoCE = -26.05% (EBIT -63.8m / Capital Employed (Equity 244.9m + L.T.Debt 187k))
 RoIC = -16.63% (negative operating profit) (NOPAT -50.4m / Invested Capital 303.3m)
 WACC = 5.22% (E(2.12b)/V(2.12b) * Re(5.22%) + D(527k)/V(2.12b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 5.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.79 | Cagr: 22.32%
 [DCF] Fair Price = unknown (Cash Flow -61.7m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.16 | Chg30d=+0.00% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.49 | Chg30d=-2.76% | Revisions=-55% | GrowthEPS=-53.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.59 | Chg30d=-2.60% | Revisions=-44% | GrowthEPS=-20.3% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -59% (up=2, down=12)